Daping Hospital of Army Medical University, Chongqing, 400042, People's Republic of China.
Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital and Chongqing Cancer Institute and Chongqing Cancer Hospital, Chongqing, 400030, People's Republic of China.
Mol Med. 2021 Mar 10;27(1):23. doi: 10.1186/s10020-021-00282-7.
To investigate effect of microRNA-325-3p (miR-325-3p) on bone metastasis of colorectal cancer (CRC) and the precise role on osteoclastogenesis.
CT-26 cells were injected into tibias to establish bone metastatic model of CRC in vivo. AgomiR-325-3p or antagomir-325-3p were injected in tail-veins of Balb/c mice to interfere the osteoclastogenesis and bone metastasis of CRC. Safranin O and Fast Green staining examined the changes of trabecular area and TRAP staining examined the osteoclast number in bone metastasis of CRC. Real-time PCR was conducted to test the RNA level of miR-325-3p and mRNA levels of TRAP and Cathepsin K in osteoclast precursors (OCPs). Dual-luciferase reporter system was utilized to identify the direct target of miR-325-3p. Conditioned medium from CT-26 cells was collected to stimulate the OCPs during osteoclastogenesis induced by RANKL and M-CSF in vitro. Western blot analysis was performed to examine the protein level of S100A4 in OCPs after interfered by agomiR-325-3p or antagomir-325-3p cultured in CM or not.
miR-325-3p downregulated in OCPs in CRC microenvironment both in vivo and in vitro. By luciferase activity assay, S100A4 was the target gene of miR-325-3p and the protein level of S100A4 in OCPs upregulated in CRC microenvironment. Overexpression of miR-325-3p inhibited the osteoclastogenesis of OCPs and it can be reversed after transfection with plasmid containing S100A4. Treatment with miR-325-3p can preserve trabecular area in bone metastasis of CRC.
miR-325-3p can prevent osteoclast formation through targeting S100A4 in OCPs. Overexpression of miR-325-3p efficiently decreased the osteoclast number and attenuated bone resorption in bone metastasis of CRC.
研究微小 RNA-325-3p(miR-325-3p)对结直肠癌(CRC)骨转移的影响及其对破骨细胞生成的确切作用。
将 CT-26 细胞注入胫骨中建立 CRC 骨转移的体内模型。尾静脉注射 agomiR-325-3p 或 antagomir-325-3p 以干扰 CRC 成骨细胞和骨转移的破骨细胞生成。番红 O 和 Fast Green 染色检测 CRC 骨转移中骨小梁面积的变化,TRAP 染色检测破骨细胞数量。实时 PCR 检测破骨细胞前体(OCPs)中 miR-325-3p 的 RNA 水平和 TRAP 和组织蛋白酶 K 的 mRNA 水平。双荧光素酶报告系统用于鉴定 miR-325-3p 的直接靶标。收集 CT-26 细胞的条件培养基,在体外 RANKL 和 M-CSF 诱导的破骨细胞生成过程中刺激 OCPs。Western blot 分析检测 OCPs 在经 agomiR-325-3p 或 antagomir-325-3p 干预后培养在 CM 中的 S100A4 蛋白水平。
miR-325-3p 在体内和体外 CRC 微环境中的 OCPs 中下调。通过荧光素酶活性测定,S100A4 是 miR-325-3p 的靶基因,CRC 微环境中 OCPs 的 S100A4 蛋白水平上调。miR-325-3p 的过表达抑制 OCPs 的破骨细胞生成,而转染含有 S100A4 的质粒后可逆转。miR-325-3p 处理可保留 CRC 骨转移中的骨小梁面积。
miR-325-3p 可通过靶向 OCPs 中的 S100A4 来防止破骨细胞形成。miR-325-3p 的过表达可有效减少 CRC 骨转移中的破骨细胞数量并减弱骨吸收。